Showing 6671-6680 of 8649 results for "".
- Holland Foundation for Sight Restoration Appoints Kila Hanrahan Director of Developmenthttps://modernod.com/news/holland-foundation-for-sight-restoration-appoints-kila-hanrahan-director-of-development/2480875/Kila Hanrahan, who has more than a decade experience in fundraising initiatives, has joined the Holland Foundation for Sight Restoration as Director of Development. “We are very excited to have Kila joining the Holland Foundation as the first employee,” said Holland Fo
- Webinar: Diabetes + Your Eyes: A Conversation Around Patient-Centered Carehttps://modernod.com/news/webinar-diabetes-your-eyes-a-conversation-around-patient-centered-care/2480869/
- Phase 4 PALADIN Study Confirms Positive Predictive Value of Corticosteroid Course Prior to Iluvien Use for IOP Outcomeshttps://modernod.com/news/phase-4-paladin-study-confirms-positive-predictive-value-of-corticosteroid-course-prior-to-iluvien-use-for-iop-outcomes/2480855/Alimera Sciences announced that the phase 4 PALADIN study confirmed the benefit of using a prior course of corticosteroid as indicated in the Iluvien U.S. label to mitigate the risk of uncontrolled IOP elevation. These results were presented at the annual Association for Researc
- Skye Bioscience Reports Enhanced IOP-Lowering of SBI-100 Formulationhttps://modernod.com/news/skye-bioscience-reports-enhanced-iop-lowering-of-sbi-100-formulation/2480846/Skye Bioscience announced that the peer-reviewed journal International Journal of Pharmaceutics published preclinical data demonstrating stronger and longer-lasting reduction of IOP when Skye’s proprietary molecule, SBI-100, is formulated as a nanoemulsion containing the
- Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at ARVOhttps://modernod.com/news/kala-pharmaceuticals-to-present-clinical-data-for-kpi-012-its-mesenchymal-stem-cell-secretome-product-for-the-treatment-of-pced-at-arvo/2480824/Kala Pharmaceuticals reported clinical data from a phase 1b trial of KPI-012, its novel, cell-free secretome therapy for the treatment of severe ocular diseases driven by impaired healing. As previously disclosed, treatment with KPI-012 was well tolerated and resulted in significant improvements
- American Academy of Optometry announces the 2022 ARVO Student Travel Fellowship Grant Recipientshttps://modernod.com/news/american-academy-of-optometry-announces-the-2022-arvo-student-travel-fellowship-grant-recipients/2480811/
- Registration Now Open for Neuro-Optometric Rehabilitation Association Annual Conferencehttps://modernod.com/news/registration-now-open-for-neuro-optometric-rehabilitation-association-annual-conference/2480810/Registration is now open for the Neuro-Optometric Rehabilitatio
- ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and ARVO 2022https://modernod.com/news/proqr-to-present-at-the-retinal-cell-and-gene-therapy-innovation-summit-and-arvo-2022/2480809/
- Study Covering 2,000 Patients Over 10 Years Using ForeseeHome AMD Remote Monitoring Shows Better Outcomes for Patientshttps://modernod.com/news/study-covering-2000-patients-over-10-years-using-foreseehome-amd-remote-monitoring-shows-better-outcomes-for-patients/2480802/
- Ziemer Receives FDA Clearance for the FEMTO Z8 NEOhttps://modernod.com/news/ziemer-receives-fda-clearance-for-the-femto-z8-neo/2480792/Ziemer Ophthalmic Systems has received FDA clearance for its latest femtosecond laser, the FEMTO Z8 NEO—the successor of Femtosecond Laser LDV Z8. The FEMTO Z8 NEO provides advanced hardware, as well as new and improved software applications. The newly designed platform offer